Infinity Pharma (INFI) Misses Q4 EPS by 8c, FY Revenue Guidance Tops Views

Infinity Pharma (NASDAQ: INFI) reported Q4 EPS of ($0.80), $0.08 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $9 million versus the consensus estimate of $18.26 million.

GUIDANCE:

Infinity Pharma sees FY2016 revenue of $225-245 million, versus the consensus of $215 million.

For earnings history and earnings-related data on Infinity Pharma (INFI) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24